EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

Company Overview

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $6.85 to $7.42
• 50-Day Range: $4.13 to $7.30
• 52-Week Range: $3.91 to $13.99
• Volume: 757,824 shs
• Average Volume: 819,533 shs
• Market Capitalization: $496.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.38
• Consensus Rating: Buy

EyePoint Pharmaceuticals Stock Analysis - MarketRank™

EyePoint Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 577th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

EyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

EyePoint Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($2.13) to ($2.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of EyePoint Pharmaceuticals is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of EyePoint Pharmaceuticals is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

EyePoint Pharmaceuticals has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.09% of the float of EyePoint Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

EyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in EyePoint Pharmaceuticals has recently decreased by 28.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

EyePoint Pharmaceuticals does not currently pay a dividend.

Dividend Growth

EyePoint Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.09% of the float of EyePoint Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

EyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in EyePoint Pharmaceuticals has recently decreased by 28.40%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.05

News Sentiment

EyePoint Pharmaceuticals has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for EyePoint Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, EyePoint Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.74% of the stock of EyePoint Pharmaceuticals is held by insiders.

Percentage Held by Institutions

99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EYPT Stock Analysis - Frequently Asked Questions

How have EYPT shares performed this year?

EyePoint Pharmaceuticals' stock was trading at $7.45 at the start of the year. Since then, EYPT stock has decreased by 3.2% and is now trading at $7.21.
View the best growth stocks for 2025 here.

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.65). The company earned $24.50 million during the quarter, compared to analyst estimates of $8.84 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 43.01% and a negative net margin of 226.57%.
Read the conference call transcript.

When did EyePoint Pharmaceuticals' stock split?

EyePoint Pharmaceuticals shares reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are EyePoint Pharmaceuticals' major shareholders?

Top institutional shareholders of EyePoint Pharmaceuticals include Adage Capital Partners GP L.L.C. (9.01%), Federated Hermes Inc. (5.94%), Vanguard Group Inc. (5.57%) and Goldman Sachs Group Inc. (2.23%). Insiders that own company stock include Ew Healthcare Partners, LP, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine and David R Guyer.
View institutional ownership trends.

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of EyePoint Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that EyePoint Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA), Advanced Micro Devices (AMD) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 5/29/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:EYPT
• CIK: 1314102
• Web: eyepointpharma.com
• Phone: (617) 926-5000
• Fax: 617-926-5050
• Employees: 120
• Year Founded: 1987

Price Target and Rating

• Average Stock Price Target: $25.38
• High Stock Price Target: $33.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +251.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.79 million
• Net Margins: -226.57%
• Pretax Margin: -226.38%
• Return on Equity: -43.01%
• Return on Assets: -31.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.50
• Quick Ratio: 5.45

Sales & Book Value

• Annual Sales: $56.04 million
• Price / Sales: 8.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.66 per share
• Price / Book: 1.27

Miscellaneous

• Outstanding Shares: 68,811,000
• Free Float: 65,016,000
• Market Cap: $496.13 million
• Optionable: Optionable
• Beta: 1.58